98 related articles for article (PubMed ID: 15571294)
1. Amidox, an inhibitor of ribonucleotide reductase, potentiates the action of Ara-C in HL-60 human promyelocytic leukemia cells.
Bauer W; Horvath Z; Höchtl T; Saiko P; Karl D; Fritzer-Szekeres M; Szekeres T
Nucleosides Nucleotides Nucleic Acids; 2004 Oct; 23(8-9):1541-4. PubMed ID: 15571294
[TBL] [Abstract][Full Text] [Related]
2. Biochemical modulation of Ara-C effects by amidox, an inhibitor of ribonucleotide reductase in HL-60 promyelocytic human leukemia cells.
Höchtl T; Horvath Z; Bauer W; Karl D; Saiko P; Elford HL; Fritzer-Szekeres M; Szekeres T
Life Sci; 2004 Jan; 74(9):1071-80. PubMed ID: 14687648
[TBL] [Abstract][Full Text] [Related]
3. Inhibition of ribonucleotide reductase by a new class of isoindole derivatives: drug synergism with cytarabine (Ara-C) and induction of cellular apoptosis.
Nandy P; Lien EJ; Avramis VI
Anticancer Res; 1999; 19(3A):1625-33. PubMed ID: 10470093
[TBL] [Abstract][Full Text] [Related]
4. Synergistic action of resveratrol, an ingredient of wine, with Ara-C and tiazofurin in HL-60 human promyelocytic leukemia cells.
Horvath Z; Saiko P; Illmer C; Madlener S; Hoechtl T; Bauer W; Erker T; Jaeger W; Fritzer-Szekeres M; Szekeres T
Exp Hematol; 2005 Mar; 33(3):329-35. PubMed ID: 15730856
[TBL] [Abstract][Full Text] [Related]
5. Cytotoxic and biochemical effects of 3,3',4,4',5,5'-hexahydroxystilbene, a novel resveratrol analog in HL-60 human promyelocytic leukemia cells.
Horvath Z; Murias M; Saiko P; Erker T; Handler N; Madlener S; Jaeger W; Grusch M; Fritzer-Szekeres M; Krupitza G; Szekeres T
Exp Hematol; 2006 Oct; 34(10):1377-84. PubMed ID: 16982330
[TBL] [Abstract][Full Text] [Related]
6. Resveratrol, an ingredient of wine, acts synergistically with Ara-C and tiazofurin in HL-60 human promyelocytic leukemia cells.
Horvath Z; Saiko P; Illmer C; Madlener S; Hoechtl T; Bauer W; Erker T; Jaeger W; Fritzer-Szekeres M; Szekeres T
Nucleosides Nucleotides Nucleic Acids; 2006; 25(9-11):1019-24. PubMed ID: 17065057
[TBL] [Abstract][Full Text] [Related]
7. N-hydroxy-N'-(3,4,5-trimethoxyphenyl)-3,4,5-trimethoxy-benzamidine, a novel resveratrol analog, inhibits ribonucleotide reductase in HL-60 human promyelocytic leukemia cells: synergistic antitumor activity with arabinofuranosylcytosine.
Saiko P; Ozsvar-Kozma M; Bernhaus A; Jaschke M; Graser G; Lackner A; Grusch M; Horvath Z; Madlener S; Krupitza G; Handler N; Erker T; Jaeger W; Fritzer-Szekeres M; Szekeres T
Int J Oncol; 2007 Nov; 31(5):1261-6. PubMed ID: 17912455
[TBL] [Abstract][Full Text] [Related]
8. A novel N-hydroxy-N'-aminoguanidine derivative inhibits ribonucleotide reductase activity: Effects in human HL-60 promyelocytic leukemia cells and synergism with arabinofuranosylcytosine (Ara-C).
Saiko P; Graser G; Giessrigl B; Lackner A; Grusch M; Krupitza G; Basu A; Sinha BN; Jayaprakash V; Jaeger W; Fritzer-Szekeres M; Szekeres T
Biochem Pharmacol; 2011 Jan; 81(1):50-9. PubMed ID: 20849828
[TBL] [Abstract][Full Text] [Related]
9. Activation of caspases and induction of apoptosis by novel ribonucleotide reductase inhibitors amidox and didox.
Grusch M; Fritzer-Szekeres M; Fuhrmann G; Rosenberger G; Luxbacher C; Elford HL; Smid K; Peters GJ; Szekeres T; Krupitza G
Exp Hematol; 2001 May; 29(5):623-32. PubMed ID: 11376876
[TBL] [Abstract][Full Text] [Related]
10. [The ribonucleotide reductase enzyme as a target for enzyme-directed chemotherapy effects of trimidox (3,4,5-trihydroxybenzohydroxamidoxim), a new inhibitor of ribonucleotide reductases].
Findenig G; Vielnascher E; Göbl R; Fritzer-Szekeres M; Szekeres T
Wien Klin Wochenschr; 1995; 107(22):694-7. PubMed ID: 8533431
[TBL] [Abstract][Full Text] [Related]
11. Trimidox, an inhibitor of ribonucleotide reductase, synergistically enhances the inhibition of colony formation by Ara-C in HL-60 human promyelocytic leukemia cells.
Fritzer-Szekeres M; Salamon A; Grusch M; Horvath Z; Höchtl T; Steinbrugger R; Jäger W; Krupitza G; Elford HL; Szekeres T
Biochem Pharmacol; 2002 Aug; 64(3):481-5. PubMed ID: 12147300
[TBL] [Abstract][Full Text] [Related]
12. Biochemical effects of piceatannol in human HL-60 promyelocytic leukemia cells--synergism with Ara-C.
Fritzer-Szekeres M; Savinc I; Horvath Z; Saiko P; Pemberger M; Graser G; Bernhaus A; Ozsvar-Kozma M; Grusch M; Jaeger W; Szekeres T
Int J Oncol; 2008 Oct; 33(4):887-92. PubMed ID: 18813804
[TBL] [Abstract][Full Text] [Related]
13. Potentiation of the activity of 1-beta-D-arabinofuranosylcytosine by the protein kinase C activator bryostatin 1 in HL-60 cells: association with enhanced fragmentation of mature DNA.
Grant S; Jarvis WD; Swerdlow PS; Turner AJ; Traylor RS; Wallace HJ; Lin PS; Pettit GR; Gewirtz DA
Cancer Res; 1992 Nov; 52(22):6270-8. PubMed ID: 1423273
[TBL] [Abstract][Full Text] [Related]
14. Iron binding capacity of didox (3,4 dihydroxybenzohydroxamic acid) and amidox (3,4 dihydroxybenzamidoxime) two inhibitors of the enzyme ribonucleotide reductase.
Fritzer-Szekeres M; Novotny L; Vachalkova A; Göbl R; Elford HL; Szekeres T
Adv Exp Med Biol; 1998; 431():599-604. PubMed ID: 9598136
[TBL] [Abstract][Full Text] [Related]
15. Deoxynucleotide pool depletion and sustained inhibition of ribonucleotide reductase and DNA synthesis after treatment of human lymphoblastoid cells with 2-chloro-9-(2-deoxy-2-fluoro-beta-D-arabinofuranosyl) adenine.
Xie KC; Plunkett W
Cancer Res; 1996 Jul; 56(13):3030-7. PubMed ID: 8674058
[TBL] [Abstract][Full Text] [Related]
16. Modulation of cytarabine metabolism in the human promyelocytic leukemia cell line HL-60 by polyhydroxy-substituted benzohydroxamic acids.
Howell SB; Gill S; Elford HL
Cancer Treat Rep; 1982 Oct; 66(10):1825-9. PubMed ID: 6957264
[TBL] [Abstract][Full Text] [Related]
17. Iron binding capacity of didox (3,4-dihydroxybenzohydroxamic acid) and amidox (3,4-dihydroxybenzamidoxime) new inhibitors of the enzyme ribonucleotide reductase.
Fritzer-Szekeres M; Novotny L; Vachalkova A; Findenig G; Elford HL; Szekeres T
Life Sci; 1997; 61(22):2231-7. PubMed ID: 9393942
[TBL] [Abstract][Full Text] [Related]
18. Augmentation of 1-beta-D-arabinofuranosylcytosine cytotoxicity in human tumor cells by inhibiting drug efflux.
Chan TC
Cancer Res; 1989 May; 49(10):2656-60. PubMed ID: 2713849
[TBL] [Abstract][Full Text] [Related]
19. Minimum dose of fludarabine for the maximal modulation of 1-beta-D-arabinofuranosylcytosine triphosphate in human leukemia blasts during therapy.
Gandhi V; Estey E; Du M; Keating MJ; Plunkett W
Clin Cancer Res; 1997 Sep; 3(9):1539-45. PubMed ID: 9815841
[TBL] [Abstract][Full Text] [Related]
20. Modulation of the cellular metabolism of cytarabine and fludarabine by granulocyte-colony-stimulating factor during therapy of acute myelogenous leukemia.
Gandhi V; Estey E; Du M; Nowak B; Keating MJ; Plunkett W
Clin Cancer Res; 1995 Feb; 1(2):169-78. PubMed ID: 9815970
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]